Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy

Cardiovascular Intervention and Therapeutics

Volumn 32, Issue 1, 2017, Pages 53-55

  Yahagi, Kazuyuki ^a   Virmani, Renu ^a   Kesavamoorthy, Bhoopalan ^b  

^a CVPATH INSTITUTE   (United States)

^b Meenakshi Hospitals   (India)

Author keywords

BRS; BVS; DAPT; Stent thrombosis; Very late scaffold thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTITHROMBOCYTIC AGENT; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; TICLOPIDINE;

ADULT; ARTICLE; BIORESORBABLE SCAFFOLD; CASE REPORT; CORONARY ANGIOGRAPHY; CORONARY ARTERY OBSTRUCTION; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; DYSLIPIDEMIA; EMERGENCY CARE; EVEROLIMUS ELUTING CORONARY STENT; HEART PALPITATION; HUMAN; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RIGHT CORONARY ARTERY; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SWEATING; THORAX PAIN; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CORONARY BLOOD VESSEL; CORONARY THROMBOSIS; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; POSTOPERATIVE COMPLICATION; PROSTHESIS DESIGN; ST ELEVATION MYOCARDIAL INFARCTION; TISSUE SCAFFOLD; TREATMENT WITHDRAWAL;

ABSORBABLE IMPLANTS; ADULT; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; EVEROLIMUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; ST ELEVATION MYOCARDIAL INFARCTION; TICLOPIDINE; TISSUE SCAFFOLDS; WITHHOLDING TREATMENT;

EID: 85008392093     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-015-0364-y     Document Type: Article

References (8)

1. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.
2. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43–54.
3. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35:777–86.
4. Kocka V, Maly M, Tousek P, Budesinsky T, Lisa L, Prodanov P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’. Eur Heart J. 2014;35:787–94.
5. Wiebe J, Mollmann H, Most A, Dorr O, Weipert K, Rixe J, et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014;103:141–8.
6. Miyazaki T, Panoulas VF, Sato K, Naganuma T, Latib A, Colombo A. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. Int J Cardiol. 2014;174:e72–4.
7. Karanasos A, van Geuns RJ, Zijlstra F, Regar E. Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy. Eur Heart J. 2014;35:1781.
8. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138–45.